The functional mimicry of a protein by an unrelated small molecule has been a formidable challenge. Now, however, the biological activity of a 166-residue hematopoietic growth hormone, erythropoietin (EPO), with its class 1 cytokine receptor has been mimicked by a 20-residue cyclic peptide unrelated in sequence to the natural ligand. The crystal structure at 2.8 A resolution of a complex of this agonist peptide with the extracellular domain of EPO receptor reveals that a peptide dimer induces an almost perfect twofold dimerization of the receptor. The dimer assembly differs from that of the human growth hormone (hGH) receptor complex and suggests that more than one mode of dimerization may be able to induce signal transduction and cell proliferation. The EPO receptor binding site, defined by peptide interaction, corresponds to the smaller functional epitope identified for hGH receptor. Similarly, the EPO mimetic peptide ligand can be considered as a minimal hormone, and suggests the design of nonpeptidic small molecule mimetics for EPO and other cytokines may indeed be achievable.
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Erythropoietin (EPO) is the primary hormone that regulates the proliferation and differentiation of immature erythroid cells (1) . In mammals, EPO is produced in fetal liver and adult kidney in response to hypoxia, and circulates in the bloodstream where it targets EPO receptor (EPOR) on committed progenitor cells in the bone marrow and other hematopoietic tissues (1) . Recombinant human erythropoietin is widely used in the treatment of patients with anemia due to renal failure, cancer chemotherapy, and AZT treatment (2) . The EPOR belongs to the cytokine receptor superfamily, which includes receptors for other hematopoietic growth factors, such as interleukins (IL) and colony-stimulating factors (CSF), as well as growth hormone (GH), prolactin, and ciliary neurotrophic factor (CNTF) (3) . The structural architecture of this family of receptors consists of three modules: a ligand binding extracellular subunit, a single transmembrane region and a cytoplasmic domain. Bazan (3) has proposed that the extracellular portion of this receptor superfamily comprises two dis-0. Livnah crete domains (named here Dl and D2), each containing approximately 100 residues that fold into a sandwich consisting of seven antiparallel 3 strands with the topology of an immunoglobulin (Ig) constant domain. Members of the family share two characteristic motifs in their extracellular domains, namely, a pair of conserved disulfide bridges in the NH2-terminal domain (D1), and a WSXWS box (4) in the COOH-terminal domain (D2). Oligomerization of one or more polypeptide chains is often essential for forming functional, high affinity receptor complexes (5) . A homodimer complex is the active form of human growth hormone receptor (hGHR) (6, 7) , and a similar model has been suggested for granulocyte-colony-stimulating factor (G-CSF), prolactin, and EPORs (5, 8 (14) . The crystal structure was determined by multiple isomorphous replacement (MIR) with two heavy-atom derivatives (Table 1 (20) , the third fibronectin-type repeat of tenascin (21) , and the D2 domain of the chaperone protein PapD (22 The quality of the map was generally good (Fig. 2) , and 94 percent of the complex structure could be fitted with the use of the graphics program 0 (54) . The register of the amino acid residues was verified from the positions of the two disulfide bridges in Dl, and the positions of the two Hg's from the mercury acetate (HgAc2) derivative, which were correctly assumed to bind to the free Cysl8e residues. The peptide interpretation was verified from another data set from a complex between EBP and an iodinated peptide (TyrP4 was substituted by p-iodo-Phe), which diffracted to 3.3 A resolution, that in difference Fourier (FIOdo -FnJl)l)MIRAS indicated the location of the iodine atoms (55) . The structure was refined by means of the slow-cooling protocol in X-PLOR 3.1 (56) and rebuilt with F. -F, 3Fo -2F0 and SIGMAA weighted (57) electron density maps. After every two cycles of refinement, a set of simulated annealing omit maps (7 to 10 percent) to reduce model bias was calculated, and the entire structure was rebuilt. After several cycles of refinement, individual temperature factors were calculated and after ten cycles of refinement and model building, the R value was 0.21 for 8.0 to 2.8 A data with F > la (13,984 reflections interacts first with strand C and then switches to interact with strand E (where C' changes its designation to strand D) forming a four-on-four strand 13 sandwich (Fig. 2B ). Dl contains the two conserved disulfide bridges linking Cys28 (PA) to Cys98 (1B) and Cys6'7 (pC') to Cys83 (PE).
The number of residues between the cysteine pairs that form the two disulfide bridges are 9 and 15 for EBP, compared to 9 and 10 in both GHR and PRLR. The longer connection between strands C' and E enables the second half of strand C' to become strand D (25) and is located in an extended chain region immediately preceding the 1G strand that would normally connect to the membrane-spanning region of EPOR (Fig. 2A) .
The quaternary structure of the complex is composed of two peptides and two receptors that form a T-shaped assembly. A noncovalent peptide dimer interacts with two receptor molecules to generate an almost perfect twofold symmetrical arrangement ( Fig. 2A) . After superposition of D2 of the two EBP molecules in the dimer, the centers of mass of the two DI domains are only Cys 6 and CysP15, which links two short 13 strands (residues 4 to 7 and 13 to 16) that are connected by a slightly distorted type I 1 turn (26) consisting of residues Gly'9-Pro"' 0-Leul' l-Thrpl 2 (15) . The f strands in each domain are represented arrows and labeled in the order they appear in the sequence. The four EBP loo that interact with the peptide ligand are labeled in black as Li, L3, L5, and L6, a the two additional putative binding loops L2, L4, for EPO as a ligand are labelec purple. The side chains of Asn52, which is a potential glycosylation site, Phe93, which was found to be an essential side chain for high affinity EPO binding, and (Fig. 2C) . Each peptide has a very close association with its other peptide partner and buries 320 A2 of its 1220 A2 molecular surface in this interaction (24) . Four hydrogen bonds between the main chains of the two peptides result in formation of a fourstranded, anti-parallel 1-pleated sheet ( Fig.   2C and Table 2 ). Two symmetric hydrophobic cores are assembled by peptide dimerization and are comprised of the disulfide bridges and the side chains of Tyr 4, PheP8, and TrpP' 3. The construction of each hydrophobic core resembles a box and places the aromatic rings of PheP8, TrpP13, and TyrP'4, (from the other peptide) and the disulfide bridge (Cys 6-CysPI5) at the corners (Fig. 2C) . The two glycine residues at either end of the peptide are not ordered.
The Figs. 2A and 3) . A portion of each peptide monomer interacts with both receptor molecules (Fig. 3) . The (Fig. 2C) , to interact with loop L3 ( Table 2 ). The EBP1-EBP2 functional sulphydryl reactive crosslinker DPDPB (27) , [1 ,4- figure) , the equivalent residues are color-coded blue (positively charged), red (glutamic acid and glutamine) and brown (the WSXWS box and other tryptophans in the extended Tr-cation system). The rr-cation system in EPOR consists of only one arginine and two tryptophan residues, which may explain the extremely low tolerance of mutating each of the tryptophans even to other aromatic residues (37, 39) . Although one of the serine residues in replaced by a glycine in the HGHR, the structure of the 1B bulge of the WSXWS box is maintained. In the HGHR (7) and PRLR (17), the Tr-cation system is more extended than in EPOR, and can be considered as two subsystems with Phe225 in HGHR and Trp'94 in PRLR at the interface between them. In the conserved Tr-cation system (top), the stacking of the conjugated residues are at -4.0 A spacings, whereas, in the additional Ir-cation system in GHR and PRLR (below), the conjugated residues are spaced -3.6 A apart. Additional Arg residues in HGHR and PRLR are contributed either from the f3F strand as in hGHbp (Arg21 1) or from PC as in PRLR (Arg147); the glutamine residue that hydrogen bonds and orients the arginine also switches strands. Sequence alignments suggest that this Arg-Gln switch could be common to other members of the class-1 cytokine receptor family. versible by reduction (28 (29) . Thus EMPI mediates formation of a soluble EBP dimer complex in solution consistent with the crystal structure. EMPI is one of a family of sequences that contain several conserved residues, besides the cysteines (10) . EMPI evolved from a peptide [AFi 1154; GGCRIGPITWVCGC] (11) that had low binding affinity (IC50 of approximately 10 ,uM) toward soluble EPOR (sEPOR) (10) . This peptide already contained the sequence GPXTW which is involved both in peptide-receptor [Gly-Pro-X-Thr; type I 1 turn] and peptide-peptide [Trp] interactions (Fig. 2C) . The next generation of peptides had a consensus sequence YXCXXGPXTWXCXP, which showed both increased binding (IC50 0.2-1 ,uM) and biological activity. The introduced tyrosine side chain, along with the Trp, plays a key role in peptide-receptor interaction and dimerization (Table 2 ). In addition, the Tyr, Trp, and disulfide bridge make the major contribution to the hydrophobic core of the peptide dimer.
The WSXWS motif. The WSAWS sequence (residues 209 to 213) occurs in a 1 bulge (25) immediately preceding 13 strand G in D2 ( Figs. 2A and 6 ) and adopts a polyproline type II helix conformation (30) . This motif does not appear to play any role in ligand binding or receptor-receptor interaction ( Fig. 2A) . The WSAWS box represents only a segment of a complex array of interactions that includes several other conserved side chains from the four-stranded 13 sheet in D2 (Fig. 6 ). Ser210 and Ser213 form hydrogen bonds with the main chain of residues 198 and 196 of adjacent strand F in a pseudo-13-sheet type interaction that resembles a modified wide 1 bulge (25) where the side-chain hydroxyl rather than the carbonyl oxygen makes the 1-sheet interaction. The polyproline type II architecture places the two Trp residues, which are three (i, i + 3) residues apart, on the same side of the 13 sheet and not on opposite sides as in standard 13-sheet or extended chain structures. The guanidinum group of Arg197 from strand F, the central residue (25) in the bulge, is positioned exactly between the two Trp indole rings to form an extended rr-cation system (31) . The three conjugated systems (32) interaction contributes little to the overall stability of the complex where the buried molecular surface area between the receptors is only 75 A2 (Fig. 3A) .
To explore the interaction of EMPI with EBP in solution, we employed a bi-EPOR HGHR on September 28, 2010 www.sciencemag.org
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Glu'57 forms a hydrogen bond with Arg'97 and presumably influences the orientation of the guanidinium group. In addition, the aliphatic portion of the Arg199 side chain makes hydrophobic contacts with the indole ring of Trp209
The structural equivalents of the WSXWS motif in hGHbp (YGEFS) and PRLR (WSAWS) take part in an even more intricate and complex array of IT-cation interactions (Fig. 6) . The extended IT-cation system in hGHbp and PRLR consists of three aromatic groups that stack between five positively charged residues. The aliphatic portions of the outermost lysine side chains also form hydrophobic interactions with the aromatic rings (Fig. 6) . A serine or threonine in positions 2 and 5 (33) maintain a common set of hydrogen bonds between their side chain hydroxyls and the main chain of the neighboring strand (Fig. 6 ). Sequence alignments and structural modeling (34) of other class-I cytokine receptor superfamily members suggest that extended ir-cation systems could exist in human thrombopoietin, IL-6, ciliary neurotrophic factor, and human IL-4 receptors (35) .
Conservation of the WSXWS motif in EPOR or its equivalent in other members of the class-I cytokine receptor family has been proposed to be essential for biological activity and was thus assumed to be part of the receptor binding site (36, 37) . For EPOR, a systematic study of 100 mutations of the WSAWS sequence demonstrates that most of the mutations of the two tryptophan and serine residues (38) resulted in molecules that did not reach the cell surface but were retained in the endoplasmic reticulum (39) . Furthermore, an Ala21' to Glu mutation resulted in better transportation from the ER to the Golgi and three to five times the number of EPOR molecules that reach the cell surface (39) . These results now indicate a role for the WSXWS box in the folding and transport of receptor to the cell surface.
Comparison with other cytokine-receptor complex structures. The overall quaternary structure of the peptide-EBP complex differs from the equivalent arrangement in the hGH-hGHbp complex. The nonsymmetric nature of the single four-helix bundle structure of the growth hormone ligand results in an asymmetric homodimerization of the receptor that corresponds to a rotation of 1590 between receptors compared to the almost perfect twofold (1800) rotation for the EBP-peptide complex (Fig. 7) A sequential mechanism of hGH binding to its receptor has been well characterized (6) . Initial high-affinity (nM) binding of the hormone with the first receptor hGHbpl results in a buried surface area of 1130 A2 on the receptor. The second hGHbp2 has a substantially smaller interface (7) with the second binding site on hGH and interacts only with the preformed (1:1) complex to generate buried surface areas of 740 A2 with hGH and 440 A2 with the first hGHbpl (7). The binding determinants of each hGHbp consist of six recognition loops (LI to L6) (Fig. 4B) , three of which (LI to L3) come from one end of the 1-sandwich structure in Dl, one from the interdomain linker, and two from D2.
Although EBP-EMP1 and hGHbp-hGH complexes have different dimeric arrangements, which in this case probably represent differences in the size and shape of the natural hormone compared to the synthetic peptide, both receptors share equivalent ligand recognition loops, LI, L3, L5, and L6 for EBP and LI to L6 for hGHbp (Fig. 4) . A nonactive PRLR, complexed with only one molecule of hGH, also uses the same contact loops (Li to L6) (17) . From the similarity of the ligand recognition sites in hGHbp and PRLR, we would expect that the binding site of EBP, when its natural EPO ligand is bound, would include two additional loops, L2 and L4 (Fig. 2) . These six loops in EBP, hGHbp, and PRLR are thus in structurally equivalent positions but vary in size, amino acid composition (41), and conformation, although the interacting portions of each loop (side or tip) remain similar; LI, L2, L3, and L5 interact mainly with their tips, and L6 interacts with its side. In one respect, this situation is similar to the complementarity-determining regions (CDRs) in antibodies, where changes in length and sequence of the six binding loops impose specificity for different antigens, but the framework itself remains constant (42) .
For the hGHbp-hGH complex, only a subset of 9 out of 33 interacting residues that make up the structural epitope of the receptor constitute a "hot spot" or functional epitope (43) (Fig. 4) gS. 4-$v# >¾ ', A S 7t frB Q Q < < X ffi -;:'S. (10) . The peptide can be assumed to form a substantially smaller contact interface with the receptor compared to the natural hormone. The peptide binding site in EBP forms an almost flat surface, which is mainly hydrophobic in nature, without any cavities or charged residues that are normally essential for the specific targeting of small molecule ligands to a receptor binding site. The hGHbp study (43) showed that only a small part of the observed structural binding site, the socalled functional epitope (43) , contributes most of the binding energy and implied that a "minimized" hormone designed to interact with this site should form sufficient interactions to activate the receptor. Using a strategy designed initially to identify peptide binders from a phage display system (10), the EPO peptide mimetic surprisingly appears to have the characteristics of a minimal hormone. Furthermore, the limited site of interaction of the agonist peptide with EBP corresponds almost exactly to the smaller functional epitope derived from alanine scanning of hGH and hGHbp (43) (Fig. 4) 
